Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia.

Andrew M Brunner

Current opinion in hematology 2023 Mar 01

filter terms:

Therapies that target the immune system are increasingly used across oncology, including in hematologic malignancies such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). While allogeneic transplant has been a key therapy in these cancers, new approaches that target the immune system are being explored including immune checkpoint therapies, antibody-drug conjugates, and cellular therapies. This review outlines updates in the preclinical rationale for immune directed therapies in MDS and AML, as well as recent clinical trials exploring these therapies. This manuscript summarizes the development of therapies targeting T cell immunoglobulin and mucin domain-containing protein 3 (TIM-3) and CD47, which are being evaluated in late phase studies in MDS and AML. It also reviews the landscape of other immune based therapies including antibody-drug conjugates, chimeric antigen receptor-T cells, bispecific antibodies, and tumor vaccines. The treatment landscape in MDS and AML is rapidly changing; with a goal of improving the quality and duration of responses, a number of immune based therapies are under investigation. This review outlines recent advances with these therapies as well as some of the challenges that remain to incorporate them into leukemia care. Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Citation

Andrew M Brunner. Novel immune directed therapies in myelodysplastic syndromes and acute myeloid leukemia. Current opinion in hematology. 2023 Mar 01;30(2):38-44